Serum Mucin Antigen (CASA) as a Marker of Amiodarone-Induced Pulmonary Toxicity | Zendy

Peter L. Devine | Zendy; W. J. Siebert | Zendy; S Morton | Zendy; B. Scells | Zendy; Rachel J. Quin | Zendy; William Heddle | Zendy; P. V. Zimmerman | Zendy; P. Donohoe | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Serum Mucin Antigen (CASA) as a Marker of Amiodarone-Induced Pulmonary Toxicity

Author(s) -

Peter L. Devine,

W. J. Siebert,

S Morton,

B. Scells,

Rachel J. Quin,

William Heddle,

P. V. Zimmerman,

P. Donohoe

Publication year - 1998

Publication title -

disease markers

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.912

H-Index - 66

eISSN - 1875-8630

pISSN - 0278-0240

DOI - 10.1155/1998/496028

Subject(s) - toxicity , pulmonary toxicity , amiodarone , mucin , medicine , pharmacology , immunology , gastroenterology , pathology , atrial fibrillation

Amiodarone is used to treat life-threatening cardiac arrhythmias. Amiodarone-induced pulmonary toxicity (APT) can be difficult to diagnose. APT may result in increased mucus production and mucin expression. Thus, serum mucin-1 was evaluated as a marker for amiodarone-induced pulmonary toxicity. Concentrations of mucin-1 in peripheral blood were determined using cancer-associated serum antigen (CASA) assay in patients taking amiodarone. Eight of ten patients who developed major amiodarone toxicity had high serum CASA levels. Patients with toxicity had a significantly higher mean rank CASA concentration compared with those without major toxicity. CASA shows potential as a marker for amiodarone-induced toxicity, particularly pulmonary toxicity.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research